Moebius Medical Ltd. is an innovative clinical stage biotechnology company that is developing novel pain relief treatments for osteoarthritis. The company was founded in 2008, and is based on a patent-protected technology that was licensed from the Hebrew University of Jerusalem, the Technion Institute and Hadassah Medical Center.

The Company’s lead product, MM-II, is a patent-protected intraarticular biolubricant injection for treatment of mild to moderate symptomatic knee osteoarthritis (OA). The product consists of proprietary liposomes whose structure facilitates cartilage surface gliding, thus reducing pain, and preventing further wear and friction that can lead to joint damage. MM-II has demonstrated its ability to reduce osteoarthritic pain and its superiority over the standard-of-care in a double blinded, randomized, controlled and trial conducted at Hadassah Medical Center, Israel.

The company has been funded by RAD Biomed – a leading biotech accelerator in Israel, PixVine Capital – a Singapore-based early stage VC fund, and Yissum – the technology transfer company of the Hebrew University of Jerusalem.